Compare BOXL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOXL | GNPX |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.2M |
| IPO Year | 2015 | 2017 |
| Metric | BOXL | GNPX |
|---|---|---|
| Price | $5.66 | $3.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 131.5K |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,743,612.00 | N/A |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.37 | N/A |
| 52 Week Low | $0.50 | $0.14 |
| 52 Week High | $10.15 | $12.97 |
| Indicator | BOXL | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 45.44 |
| Support Level | $0.90 | $0.73 |
| Resistance Level | $8.42 | $5.24 |
| Average True Range (ATR) | 1.28 | 0.56 |
| MACD | 0.13 | -0.26 |
| Stochastic Oscillator | 36.64 | 10.66 |
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).